Table 1.
Patients’ characteristics
| (A) | n = 12 | ||
|---|---|---|---|
| WHO Classification | |||
| RAEB-2 | 6 (50%) | ||
| AML 20–30 % | 6 (50%) | ||
| IPSS Cytogenetic Risk | |||
| Good | 3 (25%) | ||
| Intermediate | 3 (25%) | ||
| Poor | 6 (50%) | ||
| Cytogenetics Abnormalities | |||
| Normal Karyotype | 3 (25%) | ||
| +8 | 1 (8%) | ||
| 7 Abnormalities | 3 (25%) | ||
| 5 Abnormalities | 3 (25%) | ||
| Complex > 3 Abnormalities | 2 (17%) | ||
| IPSS Classification | |||
| Low | 0 | ||
| Intermediate 1 | 0 | ||
| Intermediate 2 | 2 (17%) | ||
| High | 10 (83%) | ||
| Aza Response Status | |||
| Failure | 8 (67%) | ||
| Relapse | 4 (33%) | ||
| Number of Aza Cycles before Relapse or Failure | 6 [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27] | ||
| (B) | |||
| Patients | Disease | IPSS Cytogenetic Risk | Cytogenetic Abnormalities |
| #1 | RAEB-2 | Intermediate | Normal |
| #2 | RAEB-2 | Intermediate | Normal |
| #3 | RAEB-2 | Intermediate | Normal |
| #4 | RAEB-2 | Intermediate | 47,XY,+8 |
| #5 | RAEB-2 | Intermediate | Normal |
| #6 | RAEB-2 | Intermediate | 46,XY(del(9)(q12q31)/47,idem,+21 |
| #7 | AML | Poor | 45,XX,-7 |
| #8 | AML | Poor | 45,XX,t(3;11)(q22,q33),del(9)(q22,q33),-7 |
| #9 | AML | Poor | 45,XX,-7, inv(3), del11q |
| #10 | AML | Intermediate | 46,XY,inv(3)(q21q26) |
| #11 | AML | Poor | 46,XX,del(5)(q13q33)/47, idem, del(1)(p3?4),+mar/46,XX |
| #12 | AML | Good | 45,X,-Y |
| (C) | |||
| Patients | IPSS Classification | AZA Response Status | Number of AZA Cycles before Relapse or Failure |
| #1 | High | Failure | 3 |
| #2 | Intermediate 2 | Relapse | 27 |
| #3 | High | Failure | 6 |
| #4 | High | Relapse | 9 |
| #5 | Intermediate 2 | Relapse | 19 |
| #6 | High | Relapse | 26 |
| #7 | High | Failure | 6 |
| #8 | High | Failure | 4 |
| #9 | High | Failure | 6 |
| #10 | High | Failure | 1 |
| #11 | High | Failure | 6 |
| #12 | High | Failure | 6 |